Please ensure Javascript is enabled for purposes of website accessibility

5 Things You Need to Know About Celgene's Future

By Keith Speights - Feb 16, 2018 at 7:31AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Hint: They're all really good.

Celgene (CELG) had a horrible, rotten, no-good, lousy year in 2017. At least that's how some people look at it.

In reality, the big biotech saw net product sales grow 16% year over year and adjusted diluted earnings per share jump 25% higher. But Celgene's share price did wind up down nearly 10% in 2017, when it had been up more than 25% at one point. That made for a very disappointing year for investors.

What does the future hold for Celgene? The company's CFO, Peter Kellogg, and Corporate Vice President of Investor Relations Patrick Flannigan spoke and fielded questions at the Leerink healthcare conference on Thursday. Here are five things you need to know about what they said concerning Celgene's future. 

Man holding crystal ball with "future" printed on it along with various years

Image source: Getty Images.

1. Good results from Q4 should continue into 2018

Celgene missed Wall Street revenue estimates in the third quarter, cut its guidance for full-year 2017, and lowered its outlook through 2020. That triple-whammy caused the stock to crumble toward the end of last year. However, the biotech came back in Q4 with great results. Peter Kellogg said at the Leerink conference that the momentum from the fourth quarter should continue into 2018.

It's important to remember why Celgene stumbled in the third quarter. Sales for psoriasis and psoriatic arthritis drug Otezla were lower than expected. There were two primary factors behind the shortfall. First, growth in the U.S. psoriasis market slowed down. Second, Celgene felt the impact of gross-to-net adjustments from managed care contracts implemented earlier in the year.

But both of those issues appear to be largely in the past. Kellogg said that Otezla could enjoy better patient access now that contracts with payers representing roughly 80% of patients have been finalized, especially since patients won't have "step edits" that require patients to take biologics first before progressing to Otezla.  

2. No need to worry about Revlimid

You might wonder how Celgene stock can trade for less than 9.4 times expected earnings. The answer, at least in part, is that many investors are worried about the biotech's prospects after Revlimid loses exclusivity. Revlimid was the second best-selling drug in the world last year, and it still generates 63% of Celgene's total revenue. 

Several generic-drug companies are challenging Revlimid's patents. If one or more of these companies succeed in their challenges, Celgene will be in trouble. Kellogg, however, noted that Celgene has already settled with one company, Natco Pharma. The deal allows Natco to market a generic version of Revlimid in the U.S. at limited volumes beginning in March 2022, with no volume restrictions after Jan. 31, 2026.

Kellogg acknowledged that investors would probably love to see Celgene settle with other parties like it has already done with Natco. He said, though, that it was "a lengthy process" to come to terms with Natco. Other challengers will need to "see the strength" of Celgene's intellectual property before further settlements are likely. Kellogg didn't appear to be concerned about Revlimid losing exclusivity earlier than 2022, though, probably because the biotech expects other generic-drug makers to eventually agree to terms similar to the Natco deal.

3. High revenue growth and margins won't go away

Celgene projects annual revenue growth between 14% and 15% through 2020. The company reported an operating margin of 58% in 2017. Can Celgene continue to achieve that kind of revenue growth and operating margins into the next decade? Kellogg thinks it can.

He noted that the acquisition of Juno Therapeutics (JUNO), expected to close in March, would drag down operating margin a little. And the higher costs associated with more complex products on the way, including cell therapies and biologics, could negatively affect margins as well. Still, Kellogg didn't think "dramatic" changes in margins would be in store.

As for revenue growth, Celgene expects to launch 10 new potential blockbusters over the next five years. These drugs could create combined peak annual sales topping $16 billion. To put that into perspective, Celgene's total revenue in 2017 was only $13 billion. And some of those candidates, notably ozanimod and bb2121, could be bigger winners than Celgene's forecast projects. 

4. Several early-stage candidates have huge potential

What about Celgene's future beyond the drugs expected to launch over the next five years? Kellogg said the company is advancing eight new programs into early-stage clinical studies. He specifically highlighted three of those programs.

Next-generation CEL-MoD (cereblon modulator) CC-92480 is moving into a phase 1 study targeting multiple myeloma. Kellogg stated that it's "an asset you're going to hear a lot about going forward." CC-93269, which is also advancing to a phase 1 study for treatment of multiple myeloma, is another early-stage candidate that he said had high potential. Kellogg also liked the prospects for CC-90010, a BET inhibitor that's being evaluated in a phase 1 study for treating solid tumors. 

5. More acquisitions to come

Celgene has announced two acquisitions already this year: Impact Biosciences and Juno. When asked if the company was going to take a breather from mergers and acquisitions (M&A) activity, Kellogg replied, "it's not in our DNA."

What kinds of deals could Celgene make? Kellogg said the biotech will continue to look at outright acquisitions of companies and assets as well as licensing deals. He said Celgene would like to get late-stage assets, although they're sometimes expensive. However, Kellogg added that if the assets are "in areas of science we think are important and have potential, we're happy to do an M&A deal."

Key takeaway

You could dismiss everything Celgene's executives said about the company's future as just spin. I think that would be misguided, though.

In my view, Celgene is in a great position for the future. I think fears about losing exclusivity for Revlimid are overblown, and I like the prospects for the biotech's pipeline candidates. Celgene's plunge in late 2017 was overdone, in my opinion, making this biotech stock one of the best buys on the market right now.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Celgene Corporation Stock Quote
Celgene Corporation
CELG
Juno Therapeutics, Inc. Stock Quote
Juno Therapeutics, Inc.
JUNO

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
322%
 
S&P 500 Returns
116%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.